Lilly stops mid-stage Alzheimer's drug study (Update)
Eli Lilly and Co. said Thursday that it stopped a mid-stage clinical trial of an experimental Alzheimer's disease drug because of potential side effects on patients' livers.
Eli Lilly and Co. said Thursday that it stopped a mid-stage clinical trial of an experimental Alzheimer's disease drug because of potential side effects on patients' livers.
Scientists at the University of Kentucky recently performed a comprehensive characterization of age-related behavioral changes in an important mouse model of Alzheimer's disease.
Highly educated individuals with mild cognitive impairment that later progressed to Alzheimer's disease cope better with the disease than individuals with a lower level of education in the same situation, according to research ...
The devastating effect of Alzheimer's disease on bilingual people has been thrown into focus in Canada, where the sudden loss of a second language can leave sufferers feeling like strangers in their own country.